Researched Medicines Industry elects new Board
Researched Medicines Industry elects new Board members
Four new members were elected to the Board of the Researched Medicines Industry Association (RMI) at its AGM held in Auckland on 24 March.
The professional and trade organisation representing companies engaged in the research, development, manufacture and marketing of prescription medicines, the RMI is governed by an eight-member Board of Directors elected annually from senior representatives of its member companies.
new members are:
• Sean Evans ( General Manager, Novartis New Zealand Limited)
• Chris Hourigan (Business Unit Director, Janssen-Cilag (New Zealand) Ltd)
• Stuart Knight (Managing Director, Roche Products (NZ) Ltd)
• Nicholas Leach (Commercial Director, Abbott Laboratories NZ Limited).
The new members join the current Board made up of Lex Henry (non-executive Chairman); Alan Carter (Vice Chairman) Country Manager, sanofi-aventis new zealand limited; Darcy Downey, Managing Director, Boehringer Ingelheim NZ Limited; Geoff McDonald, General Manager, GlaxoSmithKline NZ Limited; and Frances Benge, Country Lead, Pfizer New Zealand Limited.
RMI CEO, Denise Wood, said the organisation would be strengthened by the blend of experience represented in the new Board.
“I’m delighted that the skills and continuity provided by the returning members fit so well with the fresh input the new members will bring to the table,” Ms Wood said.